Tumour heterogeneity and resistance to cancer therapies

Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas

(2017) June-Koo Lee et al.   JOURNAL OF CLINICAL ONCOLOGY

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

(2017) Imane Chaib et al.   JNCI-Journal of the National Cancer Institute

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

(2017) Christopher Abbosh et al.   NATURE

Tracking the Evolution of Non–Small-Cell Lung Cancer

(2017) Mariam Jamal-Hanjani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

(2017) Solange Peters et al.   NEW ENGLAND JOURNAL OF MEDICINE

Origins of lymphatic and distant metastases in human colorectal cancer

(2017) Kamila Naxerova et al.   SCIENCE

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

(2017) Emmet J. Jordan et al.   Cancer Discovery

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

(2017) Imane Chaib et al.   JNCI-Journal of the National Cancer Institute

Multiregion Whole-Exome Sequencing Uncovers the Genetic Evolution and Mutational Heterogeneity of Early-Stage Metastatic Melanoma

(2016) K. Harbst et al.   CANCER RESEARCH

Regression of Chemotherapy-Resistant Polymerase   (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab

(2016) A. D. Santin et al.   CLINICAL CANCER RESEARCH

Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)

(2016) C. Karlovich et al.   CLINICAL CANCER RESEARCH

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer

(2016) Geoffrey R. Oxnard et al.   JOURNAL OF CLINICAL ONCOLOGY

LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts

(2016) S. Ramalingam et al.   Journal of Thoracic Oncology

Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

(2016) Daniel R Gomez et al.   LANCET ONCOLOGY

Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer

(2016) Kenichi Suda et al.   LUNG CANCER

Spatial intratumoral heterogeneity and temporal clonal evolution in esophageal squamous cell carcinoma

(2016) Jia-Jie Hao et al.   NATURE GENETICS

Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer

(2016) Andrew McPherson et al.   NATURE GENETICS

Clonal evolution of chemotherapy-resistant urothelial carcinoma

(2016) Bishoy M Faltas et al.   NATURE GENETICS

A framework for understanding and targeting residual disease in oncogene-driven solid cancers

(2016) Trever G Bivona et al.   NATURE MEDICINE

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

(2016) Aaron N Hata et al.   NATURE MEDICINE

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

(2016) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade

(2016) Valerie Lee et al.   ONCOLOGIST

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer

(2016) Beth O. Van Emburgh et al.   Nature Communications

Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy

(2016) John M. Findlay et al.   Nature Communications

Dynamic clonal equilibrium and predetermined cancer risk in Barrett’s oesophagus

(2016) Pierre Martinez et al.   Nature Communications

Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells

(2016) Michael Ramirez et al.   Nature Communications

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

(2016) Jacob J. Chabon et al.   Nature Communications

Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy

(2016) T. M. Johanns et al.   Cancer Discovery

Polyclonal SecondaryFGFR2Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma

(2016) Lipika Goyal et al.   Cancer Discovery

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

(2016) J. F. Gainor et al.   Cancer Discovery

The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program “CASCADE”

(2016) Peter Savas et al.   PLOS MEDICINE

Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes

(2015) F. A. San Lucas et al.   ANNALS OF ONCOLOGY

Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution

(2015) Nicholas McGranahan et al.   CANCER CELL

HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL

(2015) R. Carson et al.   CLINICAL CANCER RESEARCH

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

(2015) M. J. Niederst et al.   CLINICAL CANCER RESEARCH

Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naive EGFR L858R-Induced Lung Adenocarcinoma

(2015) V. Pirazzoli et al.   CLINICAL CANCER RESEARCH

Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses

(2015) T. K. Sundaresan et al.   CLINICAL CANCER RESEARCH

Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients

(2015) C. P. Paweletz et al.   CLINICAL CANCER RESEARCH

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts

(2015) K. Kemper et al.   EMBO Molecular Medicine

Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non–Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI

(2015) Akito Hata et al.   Journal of Thoracic Oncology

The evolutionary history of lethal metastatic prostate cancer

(2015) Gunes Gundem et al.   NATURE

Spatial genomic heterogeneity within localized, multifocal prostate cancer

(2015) Paul C Boutros et al.   NATURE GENETICS

Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue

(2015) Colin S Cooper et al.   NATURE GENETICS

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer

(2015) Gorjan Hrustanovic et al.   NATURE MEDICINE

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

(2015) Giulia Siravegna et al.   NATURE MEDICINE

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

(2015) Kenneth S Thress et al.   NATURE MEDICINE

Studying clonal dynamics in response to cancer therapy using high-complexity barcoding

(2015) Hyo-eun C Bhang et al.   NATURE MEDICINE

Pan-cancer analysis of the extent and consequences of intratumor heterogeneity

(2015) Noemi Andor et al.   NATURE MEDICINE

Subclonal diversification of primary breast cancer revealed by multiregion sequencing

(2015) Lucy R Yates et al.   NATURE MEDICINE

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Genetic Evolution of Melanoma from Precursor Lesions

(2015) A. Hunter Shain et al.   NEW ENGLAND JOURNAL OF MEDICINE

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma

(2015) Brian A. Walker et al.   Nature Communications

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

(2015) Matthew J. Niederst et al.   Nature Communications

Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA

(2015) Evgeny Izumchenko et al.   Nature Communications

Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer

(2015) Matthew K.H. Hong et al.   Nature Communications

Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer

(2015) E. M. Tricker et al.   Cancer Discovery

Tracking the Genomic Evolution of Esophageal Adenocarcinoma through Neoadjuvant Chemotherapy

(2015) N. Murugaesu et al.   Cancer Discovery

APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity

(2015) C. Swanton et al.   Cancer Discovery

Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer

(2015) M. Russo et al.   Cancer Discovery

Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets

(2015) P. K. Brastianos et al.   Cancer Discovery

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor

(2015) Z. Piotrowska et al.   Cancer Discovery

Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer

(2015) E. L. Kwak et al.   Cancer Discovery

Pancreatic Cancer Metastases Harbor Evidence of Polyclonality

(2015) R. Maddipati et al.   Cancer Discovery

NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer

(2015) Collin M. Blakely et al.   Cell Reports

Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing

(2014) H. A. Yu et al.   ANNALS OF ONCOLOGY

Genetic and Phenotypic Diversity in Breast Tumor Metastases

(2014) V. Almendro et al.   CANCER RESEARCH

The Cancer Stem Cell Marker Aldehyde Dehydrogenase Is Required to Maintain a Drug-Tolerant Tumor Cell Subpopulation

(2014) D. Raha et al.   CANCER RESEARCH

Discovery of biclonal origin and a novel oncogene SLC12A5 in colon cancer by single-cell sequencing

(2014) Chang Yu et al.   CELL RESEARCH

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

(2014) Mark G. Kris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers

(2014) Allison S. Cleary et al.   NATURE

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor

(2014) Dejan Juric et al.   NATURE

Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing

(2014) Marco Gerlinger et al.   NATURE GENETICS

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage

(2014) Aaron M Newman et al.   NATURE MEDICINE

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

(2014) Adam S. Crystal et al.   SCIENCE

Spatial and temporal diversity in genomic instability processes defines lung cancer evolution

(2014) E. C. de Bruin et al.   SCIENCE

Tumor clone dynamics in lethal prostate cancer

(2014) S. Carreira et al.   Science Translational Medicine

EGFR Variant Heterogeneity in Glioblastoma Resolved through Single-Nucleus Sequencing

(2014) J. M. Francis et al.   Cancer Discovery

Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies

(2014) O. Abdel-Wahab et al.   Cancer Discovery

Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations

(2014) Y. Y. Janjigian et al.   Cancer Discovery

The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling

(2014) Alexander Sankin et al.   Cancer Medicine

Elevated APOBEC3B Correlates with Poor Outcomes for Estrogen-Receptor-Positive Breast Cancers

(2014) Anieta M. Sieuwerts et al.   Hormones & Cancer

Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF

(2013) Rizwan Haq et al.   CANCER CELL

The Evolution of Melanoma Resistance Reveals Therapeutic Opportunities

(2013) M. D. Thakur et al.   CANCER RESEARCH

Punctuated Evolution of Prostate Cancer Genomes

(2013) Sylvan C. Baca et al.   CELL

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

(2013) Muhammed Murtaza et al.   NATURE

Evidence for APOBEC3B mutagenesis in multiple human cancers

(2013) Michael B Burns et al.   NATURE GENETICS

An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers

(2013) Steven A Roberts et al.   NATURE GENETICS

Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1

(2013) Mark M. Awad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Detection and Clinical Significance of Intratumoral EGFR Mutational Heterogeneity in Chinese Patients with Advanced Non-Small Cell Lung Cancer

(2013) Hua Bai et al.   PLoS One

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

Single-Cell Exome Sequencing Reveals Single-Nucleotide Mutation Characteristics of a Kidney Tumor

(2012) Xun Xu et al.   CELL

Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers

(2012) Ramaswamy Govindan et al.   CELL

The Life History of 21 Breast Cancers

(2012) Serena Nik-Zainal et al.   CELL

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

(2012) Sandra Misale et al.   NATURE

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

(2012) Luis A. Diaz Jr et al.   NATURE

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

(2012) Li Ding et al.   NATURE

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA

(2012) T. Forshew et al.   Science Translational Medicine

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Tumour evolution inferred by single-cell sequencing

(2011) Nicholas Navin et al.   NATURE

Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling

(2011) J. Chmielecki et al.   Science Translational Medicine

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

(2010) Alexa B. Turke et al.   CANCER CELL

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

(2010) Sreenath V. Sharma et al.   CELL

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

(2010) Jianming Zhang et al.   NATURE

The patterns and dynamics of genomic instability in metastatic pancreatic cancer

(2010) Peter J. Campbell et al.   NATURE

Distant metastasis occurs late during the genetic evolution of pancreatic cancer

(2010) Shinichi Yachida et al.   NATURE

Genomic instability — an evolving hallmark of cancer

(2010) Simona Negrini et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Tumor Self-Seeding by Circulating Cancer Cells

(2009) Mi-Young Kim et al.   CELL

A small-cell lung cancer genome with complex signatures of tobacco exposure

(2009) Erin D. Pleasance et al.   NATURE

Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis

(2009) Andrew J. Holland et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Cancer Stem Cells Contribute to Cisplatin Resistance in Brca1/p53-Mediated Mouse Mammary Tumors

(2008) N. Shafee et al.   CANCER RESEARCH

Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

(2008) Charles D. Blanke et al.   JOURNAL OF CLINICAL ONCOLOGY

Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy

(2008) X. Li et al.   JNCI-Journal of the National Cancer Institute

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE